Category

Archives

mTOR

Rapalogues as hCES2A Inhibitors: In Vitro and In Silico Investigations

9 views | Nov 17 2020

Cheng-Cheng Shi et al. demonstrated that several marketed rapalogues were potent and specific hCES2A inhibitors, and these agents could serve as leading compounds for the development of more efficacious hCES2A inhibitors to modulate the pharmacokinetic profiles and toxicity of hCES2A-substrate drugs (such as the anticancer agent irinotecan). [Read the Full Post]

A phase I trial of temsirolimus and erlotinib in patients with refractory solid tumors

11 views | Nov 15 2020

Haeseong Park et al. found the he combination of temsirolimus and erlotinib at the RP2D was well tolerated, and the regimen resulted in prolonged disease stabilization in selected patients (NCT00770263). [Read the Full Post]

mTOR Inhibition Ablates Cisplatin-Resistant Salivary Gland Cancer Stem Cells

12 views | Oct 25 2020

T Nakano et al.suggested that a combination of an mTOR inhibitor and platinum-based chemotherapy might be beneficial to patients with salivary gland mucoepidermoid carcinoma. [Read the Full Post]

A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia

17 views | Oct 22 2020

Fabian Lang et al.thought that combined inhibition of PI3K and mTOR inhibited a clinically meaningful driver pathway in a small subset of patients with ALL, with no benefit in patients with AML. [Read the Full Post]

HPV-induced Nurr1 promotes cancer aggressiveness, self-renewal, and radioresistance via ERK and AKT signaling in cervical cancer

17 views | Oct 20 2020

Peter Kok-Ting Wan et al. provided that BEZ, but not GSK, could abolish Nurr1-enhanced radioresistance, suggesting its potential value for radiosensitizing CSLCs in the clinical setting. [Read the Full Post]

The PI3K/mTOR dual inhibitor GSK458 potently impedes ovarian cancer tumorigenesis and metastasis

18 views | Oct 10 2020

Yangjiong Xiao et al. concluded that GSK458 might serve as an attractive candidate to treat ovarian cancer. [Read the Full Post]

Omipalisib Inhibits Esophageal Squamous Cell Carcinoma Growth Through Inactivation of Phosphoinositide 3-Kinase (PI3K)/AKT/Mammalian Target of Rapamycin (mTOR) and ERK Signaling

22 views | Oct 05 2020

Dong-Shan Zhu et al. supported the rationale for using omipalisib as a therapeutic approach in ESCC patients. [Read the Full Post]

Dual Inhibition of Autophagy and PI3K/AKT/MTOR Pathway as a Therapeutic Strategy in Head and Neck Squamous Cell Carcinoma

19 views | Oct 05 2020

Monique Bernard et al. suggested a broader application for this combination therapy that could be promptly translated to in vivo studies. [Read the Full Post]

Tyrosyl-DNA phosphodiesterase and the repair of 3'-phosphoglycolate-terminated DNA double-strand breaks

0 views | Sep 03 2020

Tong Zhou et al. suggested a role for TDP1 in repair of 3'-PG double-strand breaks in vivo. [Read the Full Post]

Inhibition of DNA-PKcs activity re-sensitizes uveal melanoma cells to radio- and chemotherapy

43 views | Sep 03 2020

Bingjie Zhang et al. demonstrated increased DNA double strand break repair as a mechanism of resistance to ionizing radiation and Selumetinib, and identified DNA-PKcs as a promising target for radio-and chemotherapy in UM patients. [Read the Full Post]